Monoclonal antibodies reactive with defined regions of the T-cell antigen receptor
Patent 5223426 Issued on June 29, 1993. Estimated Expiration Date: June 29, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/331, Immunoglobulin or antibody binds a specifically identified amino acid sequence424/144.1, Receptor integral to or derived from a lymphocytic or lymphocytic-like cell (e.g., NK cell, etc.)424/154.1, T lymphocytic cell (e.g., T cell, thymocyte, etc.)530/387.1, Immunoglobulin, antibody, or fragment thereof, other than immunoglobulin antibody, or fragment thereof that is conjugated or absorbed530/387.9, Binds specifically-identified amino acid sequence530/388.22, Binds receptor (e.g., transferrin receptor, Fc receptor, dihydropyridine receptor, IL-2 receptor, etc.)530/388.75Binds T-lymphocytic cell or component or product thereof (e.g., T cell, thymocyte, T-lineage bone marrow cell, T-lymphoblastoid cell, T-lineage acute lymphoblastic leukemia cell, T-lymphocytic cell-surface antigen, etc.)
The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed and , which react with two different epitopes on the framework region of the monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with ଲ chain variable regions V댥.3 and V댨.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody δTCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.
Other References
Sim et al, Nature vol. 312 pp. 771-775 1984
Saito et al, Nature vol. 309 Jun. 1984, pp. 757-762
Minami et al, The Journal of Biol Chem vol. 262 Sep. 1987, pp. 13342-13347
Fabbi et al., Eur J Imn. 15 1985 pp. 821-827
Brenner et al, The J of Im. vol. 138 1502-1509 Mar. 1, 1987
Acuto et al, Cell vol. 34, pp. 717-726 1983
Kappler Cell vol. 35 1983 pp. 295-302
Maecker and Levy (1989), J. Immunol. 142:1395-1404
Posnett et al. (1986), Proc. Nat'l Acad. Sci. USA 83: 7888-7892
Boylston et al. (1986), J. Immunol. 137: 741-744
Bigler and Chiorazzi, (1987) in the Molecular Basis of B-Cell Differentiation and Function, Ferrerini and Pernis, eds., Plenum Press, pp. 123-130
Bigler et al. (1985), J. Exp. Med. 161: 1450-1463
Bigler et al. (1983), J. Exp. Med. 158: 1000-1005
Spits et al. (1985), J. Immunol. 135: 1922-1928
Samelson et al. (1983), Proc. Nat'l Acad. Sci. U.S.A. 80: 6972-6976
Reinherz et al. (1984), Immunol. Rev. 81: 95-129
Meuer et al. (1983), J. Exp. Med. 157: 705-719
McIntyre and Allison (1983), Cell 34: 739-746
Marchalonis (1987), Antigen-Specific T-Cell Receptors and Factors, vols. I and II, Marchalonis (Ed.), CRC Press, Boca Raton, Fla., Table of Contents and pp. 18-21
Brenner et al. (1984), J. Exp. Med. 160:541-551
Tian et al. (1989) FASEB J., 3: A486 (and poster)
Borst et al. (1987), J. Immunol. 139: 1952-1959
Brenner et al. (1987), J. Immunol. 138: 1502-1509
Maecker et al. (1987), J. Immunol. Methods 98: 219-226
Picker et al. (1987), Am. J. Pathol. 129: 434-440
Ng et al. (1988), Am. J. Pathol. 132: 365-371
Moller et al. (1988), J. Clin. Invest. 82: 1183-1191
Tillinghast et al. (1986), Science 233: 879- 883
Waldmann et al. (1985), New Eng. J. Med. 313: 776-783
Schluter et al. (1986), Proc. Nat'l Acad. Sci. U.S.A. 83: 1872-187
Kappler et al. (1989), Science 244: 811-813
Brennan et al. (1988), J. Autoimmum. 1: 319-326
Grossi et al. (1989), Proc. Nat'l Acad. Sci. U.S.A. 86: 1619-1623
Wu et al. (1988), J. Immunol. 141: 1476-1479
Augustin et al. (1989), Nature 340: 239-241
Ferrini et al. (1987), J. Exp. Med. 166: 277-282
Brenner et al. (1986) Nature 322: 145-149
Compana et al. (1989), J. Immunol. 142: 57-66
Janson et al. (1989a), Cancer Immunol. Immunother. 28: 225-232
Janson et al. (1989b), in Human Tumor Antigens and Specific Tumor Therapy, Alan R. Liss, Inc. pp. 277-286
Wraith et al. (1989), Cell 57: 709-715
Howell et al. (1989), Science 246:668-670
Ashwell et al. (1987), Science 237: 61-64
Urban et al. (1988), Cell 54: 577-592
Acha-Orbea et al. (1988), Cell 54: 263-273
Vacchio and Hodes (1989), J. Exp. Med. 170: 1335-1346
Webb and Sprent (1987), J. Exp. Med. 165: 584-589
Janson et al. (1987), Scand. J. Immunol. 26: 237-246
Behlke et al. (1987), J. Exp. Med. 165: 257-262
Fowlkes et al. (1987) Nature 329: 251-254
Payne et al. (1988) Proc. Nat'l Acad. Sci. U.S.A. 85: 7695-7698
Staerz et al. (1985), J. Immunol. 134: 3994-4000
Haskins et al. (1984), J. Exp. Med. 160: 452-471
Chan and Takei (1986), J. Immunol. 136: 1346-1355
Guy et al. (1989), Science 244: 1477-1480
Traunecker et al, Eur. J. Immunol. 16: 851-854 1986, "A Novel Approach for Preparing Anti-T-Cell Receptor Constant Region Antibodies